目的 探讨安络化纤丸联合非诺贝特胶囊治疗原发性胆汁性肝硬化的临床疗效。方法 选取2023年3月—2025年2月在邢台市中心医院就诊的原发性胆汁性肝硬化患者，共计94例，将所有患者按随机数字表法分为对照组和治疗组，每组各47例。对照组服用非诺贝特胶囊，1粒/次，1次/d。治疗组患者在对照组基础上温水送服安络化纤丸，6 g/次，2次/d。两组患者均持续治疗3个月。比较两组患者的治疗效果、主要症状改善时间、肝硬化程度、肝功能指标和血清炎症因子。结果 对照组的总有效率为85.11%，治疗组的总有效率为97.87%，两组组间比较差异显著（P＜0.05）。治疗组黄疸、皮肤瘙痒、乏力、消化道不适改善时间均明显短于对照组（P＜0.05）。两组治疗后的肝脏硬度值（LSM）均显著降低（P＜0.05），且治疗组治疗后肝脏LSM低于对照组（P＜0.05）。两组治疗后的丙氨酸转氨酶（ALT）、总胆红素（TB）、直接胆红素（DB）均显著降低（P＜0.05），且治疗组治疗后ALT、TB、DB均低于对照组（P＜0.05）。两组治疗后的血清前蛋白胱抑素（PGRN）、白细胞介素-23（IL-23）、白细胞介素-8（IL-8）水平均显著降低（P＜0.05）；治疗组治疗后的血清PGRN、IL-23、IL-8水平低于对照组（P＜0.05）。结论 安络化纤丸联合非诺贝特胶囊可提高原发性胆汁性肝硬化的治疗效果，改善临床症状、肝脏硬度和肝功能，降低炎症反应。

Objective To investigate the efficacy of Anluo Huaxian Pills combined with Fenofibrate Capsules in treatment of primary biliary cirrhosis. Methods A total of 94 patients with primary biliary cirrhosis who were treated at Xingtai Central Hospital from March 2023 to February 2025 were selected. All patients were divided into control group and treatment group using a random number table, with 47 cases in each group. The control group was po administered with Fenofibrate Capsules, 1 capsule/time, once daily. The treatment group was poadministered with Anluo Huaixian Tablets with warm water on the base of the control group, 6 g/time, twice daily. Two groups were treated for 3 months. The therapeutic efficacy, time to symptom improvement, degree of cirrhosis, liver function indicators, and serum inflammatory factors were compared between two groups. Results The total effective rate in the control group was 85.11%, while that in the treatment group was 97.87%, with a significant difference between two groups (P < 0.05). The improvement times for jaundice, skin itching, fatigue, and gastrointestinal discomfort were significantly shorter than those of the treatment group (P < 0.05). After treatment, the liver stiffness measurement (LSM) values in two groups were significantly decreased (P < 0.05), and the LSM in the treatment group was lower than that in the control group (P < 0.05). After treatment, the levels of alanine aminotransferase (ALT), total bilirubin (TB), and direct bilirubin (DB) in two groups were significantly reduced (P< 0.05). After treatment, the levels of ALT, TB, and DB in the treatment group were lower than those in the control group (P < 0.05). The serum levels of pre protein cystatin (PGRN), interleukin-23 (IL-23), and interleukin-8 (IL-8) were significantly reduced in two groups after treatment (P< 0.05). The serum levels of PGRN, IL-23, and IL-8 in the treatment group were lower than those in the control group after treatment (P < 0.05). Conclusion The combination of Anluo Huaxian Pills and Fenofibrate Capsules can improve the therapeutic effect of primary biliary cirrhosis, improve clinical symptoms, liver hardness, and function, and reduce inflammatory reactions.

R975

邢台市重点研发计划自筹项目（2024ZC213）